AGTC APPLIED GENETIC TECHNOLOGIES

AGTC to Present at the Wedbush PacGrow Virtual Healthcare Conference on August 11, 2020

AGTC to Present at the Wedbush PacGrow Virtual Healthcare Conference on August 11, 2020

GAINESVILLE, Fla. and CAMBRIDGE, Mass., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that Sue Washer, President & Chief Executive Officer, will present at the Wedbush PacGrow Virtual Healthcare Conference on Tuesday, August 11, 2020 at 10:20 am ET.

A live audio webcast of the presentation will be available by visiting . A replay will be available on the Company's website following the event.

About AGTC

AGTC is a clinical-stage biotechnology company developing genetic therapies for people with rare and debilitating ophthalmic, otologic and central nervous system (CNS) diseases. AGTC is a leader in designing and constructing all critical gene therapy elements and bringing them together to develop customized therapies that address real patient needs. Initially focusing on ophthalmology, we are leveraging our best-in-class investigational technology platform to potentially improve vision for patients with an inherited retinal disease. AGTC has active clinical trials in X-linked retinitis pigmentosa and achromatopsia (ACHM CNGB3 & ACHM CNGA3). Our pre-clinical programs build on our industry leading AAV manufacturing technology and expertise. AGTC is advancing multiple important pipeline candidates to address substantial unmet clinical need in optogenetics, otology and CNS disorders.

IR/PR CONTACTS: 

David Carey (IR) or Glenn Silver (PR)

Lazar FINN Partners

T: (212) 867-1768 or (646) 871-8485

or

Corporate Contact:

Bill Sullivan

Chief Financial Officer

Applied Genetic Technologies Corporation

T: (617) 843-5728

Stephen Potter

Chief Business Officer

Applied Genetic Technologies Corporation

T: (617) 413-2754

EN
04/08/2020

Underlying

AGTCAPPLIED GENETIC TECHNOLOGIES

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on APPLIED GENETIC TECHNOLOGIES

 PRESS RELEASE
Free
AGTC APPLIED GENETIC...

Beacon Therapeutics Announces Positive Phase 2 Interim 6-Month Data fr...

Beacon Therapeutics Announces Positive Phase 2 Interim 6-Month Data from DAWN Trial of Laru-zova in Patients with X-linked Retinitis Pigmentosa (XLRP) at ARVO 2025 Data showed improvements across several key measures of visual function, including low luminance visual acuity and microperimetry Laru-zova was generally well-tolerated by DAWN participants at 6 months LONDON and CAMBRIDGE, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- Beacon Therapeutics Holdings Limited (‘Beacon Therapeutics’ or ‘the Company’), a leading clinical-stage biotechnology company with a mission to save and restore the ...

May 6, 2025 1 EN
 PRESS RELEASE
Free
AGTC APPLIED GENETIC...

Syncona Limited Portfolio Company Successfully Completes Tender Offer ...

Syncona Limited Portfolio Company Successfully Completes Tender Offer and Acquisition of Applied Genetic Technologies Corporation GAINESVILLE, Fla. and CAMBRIDGE, Mass., Dec. 01, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (“AGTC” or the “Company”) (Nasdaq: AGTC), announced today the successful completion of the previously announced tender offer (the “Offer”) to purchase all of the issued and outstanding shares of common stock of AGTC by a portfolio company of Syncona Limited (LON: SYNC) (“Syncona”). The Offer, as extended, expired at 5:00 p.m., Eastern Time, on Nove...

December 1, 2022 1 EN
 PRESS RELEASE
Free
AGTC APPLIED GENETIC...

Syncona Limited Portfolio Company Extends Tender Offer to Acquire Appl...

Syncona Limited Portfolio Company Extends Tender Offer to Acquire Applied Genetic Technologies Corporation GAINESVILLE, Fla. and CAMBRIDGE, Mass., Nov. 29, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (“AGTC” or the “Company”) (Nasdaq: AGTC), announced today that a portfolio company of Syncona Limited (LON: SYNC) (“Syncona”) has extended the expiration of its previously announced tender offer to purchase all of the issued and outstanding shares of AGTC common stock for $0.34 per share in cash at closing, plus up to an additional $0.73 per share payable pursuant to con...

November 29, 2022 1 EN
 PRESS RELEASE
Free
AGTC APPLIED GENETIC...

*FINAL REMINDER* AGTC Urges Shareholders to Tender Their Shares by Nov...

*FINAL REMINDER* AGTC Urges Shareholders to Tender Their Shares by November 28, 2022 *FINAL REMINDER* GAINESVILLE, Fla. and CAMBRIDGE, Mass., Nov. 28, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), President and Chief Executive Officer, Sue Washer, reminds AGTC stockholders: A Syncona Limited portfolio company has commenced a tender offer to purchase all outstanding shares of AGTC common stock at a price per share of $0.34 in cash plus the right for AGTC stockholders to receive additional aggregate payments of up to $0.73 per share upon the achievement ...

November 28, 2022 1 EN
David Nierengarten ... (+2)
  • David Nierengarten
  • Dennis Pak
AGTC APPLIED GENETIC TECHNOLOGIES
11/25/22 November 25, 2022 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch